This pool includes 8 peptides derived from a peptide scan (15mers with 11 aa overlap) through the entire Non-structural Protein 7b (Protein ID: P0DTD8) of SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) for T cell assays.
This pool includes 13 peptides derived from a peptide scan (15mers with 11 aa overlap) through the entire Non-Structural protein 6 (Protein ID: P0DTC6) of SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) for T cell assays.
GenCRISPR™ Ultra eSpCas9-2NLS-GMP is utilized for CRISPR gene editing applications. The Cas9 nuclease forms a stable ribonucleoprotein (RNP) complex with the guide RNA (gRNA) component. With the help of two nuclear localization signals (NLS) expressed with the Cas9 nuclease, the RNP complex enters the nucleus and cleaves target gene. When compared with a plasmid-based delivery system, the RNP delivery system has been observed to increase the on-target gene editing efficiency and decrease off-target effects.
This pool includes 7 peptides derived from a peptide scan (15mers with 11 aa overlap) through the entire ORF10 Protein (Protein ID: A0A663DJA2) of SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) for T cell assays (e.g. ELISPOT).
This peptide is well suited to the quantitative determination of A 42 peptide. Alzheimer’s disease (AD) is characterized by the presence of extracellular plaques and intracellular neurofibrillary tangles (NFTs) in the brain. The major protein component of these plaques is beta amyloid peptide (A), a 40- to 43- amino-acid peptide cleaved from amyloid precursor protein by secretase (BACE) and a putative (gamma) secretase. Increased release of the ‘longer forms’ of A peptide, A 42 and A 43, which have a greater tendency to aggregate than A 40, occurs in individuals expressing certain genetic mutations, expressing certain ApoE alleles or may other, still undiscovered factors.
The prolactin releasing hormone receptor PRLHR also named PrRP receptor is a G-protein coupled receptor that binds the prolactin releasing hormone. RT-PCR analysis showed expression of PRLHR in the human brain, pituitaries, normal portions of adrenal glands and various tumor tissues. Northern blot analysis showed high expression of PRLHR only in tumor tissues of pheochromocytomas, indicating that PRLHR expression is high in pheochromocytomas. The present study has shown that PRLHR mRNA was widely expressed in the brain tissues, pituitaries, adrenal glands and various tumors. The high expression of PRLHR receptor in pheochromocytomas suggests potential pathophysiological roles of PRLHR in these tumors